Publisher
Springer Science and Business Media LLC
Subject
Urology,Obstetrics and Gynecology
Reference22 articles.
1. Zitzmann M. Testosterone replacement treatment in older people with and without co-morbidities. Internist (Berl). 2020;61(6):549–57. https://doi.org/10.1007/s00108-020-00796-y (German).
2. Sterling J, Bernie AM, Ramasamy R. Hypogonadism Easy to define, hard to diagnose, and controversial to treat. Can Urol Assoc J. 2015;9(1 2):65–8. https://doi.org/10.5489/cuaj.2416.
3. Snyder CN, Clark RV, Caricofe RB, Bush MA, Roth MY, Page ST, Bremner WJ, Amory JK. Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. J Androl. 2010;31(6):527–35. https://doi.org/10.2164/jandrol.109.009746.
4. Amory JK, Bush MA, Zhi H, Caricofe RB, Matsumoto AM, Swerdloff RS, Wang C, Clark RV. Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days. J Urol. 2011;185(2):626–32. https://doi.org/10.1016/j.juro.2010.09.089.
5. Lipocine, Inc. Lipocine announces ABPM labeling study results consistent with recently approved testosterone replacement therapy [press release]. March 27, 2019. ProMED-mail website. https://ir.lipocine.com/2019-03-27-Lipocine-Announces-ABPM-Labeling-Study-Results-Consistent-with-Recently-Approved-Testosterone-Replacement-Therapy. Accessed May 17, 2021.